ArticleThe oncologist2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.Cancer discovery · 2019Trial
- A PDCD4-Based Gene Expression Signature Predicts Overall Survival in Renal Cell Carcinoma: A TCGA-Based Discovery and External Validation Study.Current issues in molecular biology · 2025Article
- Practical management of renal cell carcinoma: integrating current approaches with advances in bone metastasis treatment.EFORT open reviews · 2024Review
- Review
- Identification of a basement membrane-based risk scoring system for prognosis prediction and individualized therapy in clear cell renal cell carcinoma.Frontiers in genetics · 2023Article
- Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.European urology open science · 2022Review
- Review
- Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma.The journal of pathology. Clinical research · 2021Article
- Role of SIRT1/AMPK signaling in the proliferation, migration and invasion of renal cell carcinoma cells.Oncology reports · 2021Observational
- Prognostic Value of Plasma hPGCancers · 2021Article
- Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment.Frontiers in cell and developmental biology · 2021Article
- Radiology- and gene-based risk stratification in small renal cell carcinoma: A preliminary study.PloS one · 2021Article
- Article
- Profiles of overall survival-related gene expression-based risk signature and their prognostic implications in clear cell renal cell carcinoma.Bioscience reports · 2020Article
- The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice.Kidney cancer (Clifton, Va.) · 2020Review
- Review
- Towards individualized therapy for metastatic renal cell carcinoma.Nature reviews. Clinical oncology · 2019Review
- Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2019Review
- DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups.Cancer cell international · 2019Article
Corrections and comments
- Commented on by
- Commented on byIn Reply.2017
Authors and funding
15 authors at 10 institutions in 5 countries.
Funding
Abstract
introductionGene-expression signatures for prognosis have been reported in localized renal cell carcinoma (RCC). The aim of this study was to test the predictive power of two different signatures, ClearCode34, a 34-gene signature model [Eur Urol 2014;66:77-84], and an 8-gene signature model [Eur Urol 2015;67:17-20], in the setting of systemic therapy for metastatic disease. MATERIALS AND
methodsMetastatic RCC (mRCC) patients from five institutions who were part of TCGA were identified and clinical data were retrieved. We trained and implemented each gene model as described by the original study. The latter was demonstrated by faithful regeneration of a figure and results from the original study. mRCC patients were dichotomized to good or poor prognostic risk groups using each gene model. Cox proportional hazard regression and concordance index (C-Index) analysis were used to investigate an association between each prognostic risk model and overall survival (OS) from first-line therapy.
resultsOverall, 54 patients were included in the final analysis. The primary endpoint was OS. Applying the ClearCode34 model, median survival for the low-risk-ccA (
conclusionThe ClearCode34 but not the 8-gene molecular model improved the prognostic predictive power of the IMDC model in this cohort of 54 patients with metastatic clear cell RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.